Skip to main content
  1. Roychowdhury S, Roth CM. Pharmacodynamic model of the dynamic response of Pseudomonas aeruginosa biofilms to drug treatments. Biomedicines, 2023; 11:2316; doi: 10.3390/biomedicines11082316.
  2. Burr A, Erickson P, Imbriani-Bento R, Sharma K, Roth C, Parekkadan B. Allometric-like scaling of AAV gene therapy for systemic protein delivery. Mol. Ther. Methods Clin. Dev., 2022; 27:368-379; doi:10.1016/j.omtm.2022.10.011.
  3. Kantamneni H, Barkund SR, Donzanti MJ, Martin D, Zhao X, He S, Riman RE, Tan M-C, Pierce MC, Roth CM, Ganapathy V, Moghe PV. Shortwave infrared emitting multicolored nanoprobes for biomarker-specific cancer imaging in vivo. BMC Cancer, 2020; article 1082; doi: 10.1186/s12885-020-07604-8.
  4. Nusblat LM, Tanna S, Roth CM, Gene silencing of HIF-2alpha disrupts glioblastoma stem cell phenotype. Cancer Drug Resist., 2020; 3:199-208; doi: 10.20517/cdr.2019.96.
  5. Higgins LM, Ganapathy V, Kantamneni H, Zhao X, Sheng Y, Tan M-C, Roth CM, Riman RE, Moghe PV, Pierce MC. Multi-scale optical imaging of rare-earth-doped nanocomposites in a small animal model. Biomed. Opt., 2018; 23:030505; doi:10.1117/1.JBO.23.3.030505.
  6. Kantamneni H, Zevon M, Donzanti MJ, Zhao X, Sheng Y, Barkund SR, McCabe LH, Banach-Petrosky W, Higgins LM, Ganesan S, Riman RE, Roth CM, Tan M-C, Pierce MC, Ganapathy V, Moghe PV. Surveillance nanotechnology for multi-organ cancer metastases. Nature Biomed. Engr., 2017; 1:993-1003; doi:10.1038/s41551-017-0167-9.
  7. Nusblat LM, Carroll MJ, Roth CM, Cross talk between M2 macrophages and glioma stem cells. Cell Oncol., 2017; 40:471-482; DOI 10.1007/s13402-017-0337-5.
  8. Gu L, Wang N, Nusblat LM, Soskind R, Roth CM, Uhrich KE. pH-responsive amphiphilic macromolecular carrier for doxorubicin delivery. Bioactive Compatible Polymers, 2017; 32:3-16; doi: 10.1177/0883911516643219.
  9. Higgins LM, Zevon M, Ganapathy V, Sheng Y, Tan MC, Riman RE, Roth CM, Moghe PV, Pierce MC. Line-scanning confocal microscopy for high-resolution imaging of rare-earth-based upconverting contrast agents. Biomed. Opt., 2015; 20:110506; doi:10.1117/1.JBO.20.11.110506.
  10. Ganapathy V, Moghe PV, Roth CM. Targeting tumor metastases: drug delivery mechanisms and challenges. Control. Rel., 2015; 219:215-223; PMCID: PMC4745901.
  11. Zevon M, Ganapathy V, Kantamneni H, Mingozzi M, Kim P, Adler D, Pierce MC, Riman RE, Roth CM, Moghe PV. CXCR4 targeted short wave infrared (SWIR) emitting nanoprobes for enhanced deep tissue imaging and micrometastatic cancer lesion detection. Small, 2015; 11:6347-6357; PMCID: PMC4763715.
  12. Shreiber DI, Moghe PV, Roth CM. Multidisciplinary “Boot Camp” Training in Cellular Bioengineering to Accelerate Research Immersion for REU Participants. Eng. Educ., 2015; 4(4):1-15;
  13. Peddada LY, Garbuzenko OB, Devore DI, Minko T, Roth CM. Delivery of antisense oligonucleotides using poly(alkylene oxide)-poly(propylacrylic acid) graft copolymers in conjunction with cationic liposomes.  Control. Rel., 2014; 194C:103-112; doi: 10.1016/j.jconrel.2014.08.023; PMCID: PMC4573985.
  14. Gu L, Nusblat LM, Tishbi N, Noble SC, Pinson CM, Mintzer E, Roth CM, Uhrich KE. Cationic amphiphilic macromolecule (CAM)-lipid complexes for efficient siRNA delivery. Control. Rel., 2014; 184:28-35; doi: 10.1016/j.jconrel.2014.04.005; PMCID: PMC4090228.
  15. Naczynski DJ, Tan MC, Zevon M, Wall B, Kohl J, Kulesa A, Chen S, Roth CM, Riman RE, Moghe PV. Rare-earth doped nanoparticles as bioactive probes for shortwave infrared in vivo imaging. Nature Commun., 2013; 4:2199; PMCID: PMC3736359.
  16. Cui M, Naczynski DJ, Zevon M, Poventud-Fuentes I, Chen S, Roth CM, Moghe PV. Multifunctional albumin nanoparticles as combination drug carriers for intra-tumoral chemotherapy. Healthc. Mater., 2013; 2:2036-2045; doi: 10.1002/adhm.201200467.
  17. Mishra S, Vaughn AD, Devore DI, Roth CM. Delivery of sirna silencing Runx2 using a multifunctional polymer-lipid nanoparticle inhibits osteogenesis in a cell culture model of heterotopic ossification. Biol., 2012; 4:1498-1507; PMC4534437.
  18. Mishra S, Peddada LY, Devore DI, Roth CM. Poly(alkylene oxide) copolymers for nucleic acid delivery. Chem. Res., 2012; 45:1057-1066; PMCID: PMC3361000.
  19. Waite CL, Roth CM. Nanoscale drug delivery systems for enhanced penetration into tumors: Current progress and opportunities. Rev. Biomed Eng., 2012; 40:21-41; PMCID:PMC3639314.
  20. Waite CL, Roth CM. Binding and transport of PAMAM-RGD in a tumor spheroid model: The effect of RGD targeting ligand density. Bioeng., 2011; PMCID: PMC3193538.
  21. Sparks SM, Waite CL, Harmon AM, Nusblat LM, Roth CM, Uhrich KE. Efficient intracellular siRNA delivery by ethyleneimine-modified nanoscale amphiphilic macromolecules.  Biosci., 2011; 11:1192-1200; PMCID: PMC3549469.
  22. Hamed SS, Roth CM. Mathematical modeling to distinguish cell cycle arrest from cell killing in chemotherapeutic concentration response curves.  Pharmacokin. Pharmacodyn., 2011; 38:385-403; doi: 10.1007/s10928-011-9199-z.
  23. Yang H, Roth CM, Ierapetritou MG. Analysis of amino acid supplementation effects on hepatocyte cultures using flux balance analysis.  OMICS, 2011; 15:449-460; doi:10.1089/omi.2010.0070.
  24. Yang H, Ierapetritou MG, Roth CM. Effects of amino acid transport limitations on cultured hepatocytes.  Chem., 2010; 152:89-98;
  25. Iyer VV, Ovacik MA, Androulakis IP, Roth CM, Ierapetritou MG. Transcriptional and metabolic flux profiling of triadimefon effects on cultured hepatocytes.  Appl. Pharmacol., 2010; 248:165-177;
  26. Iyer VV, Yang H, Ierapetritou MG, Roth CM. Effects of glucose and insulin on HepG2-C3A cell metabolism.  Bioeng., 2010; 107:347-356; DOI: 10.1002/bit.22799.  Selected for Spotlight feature.
  27. Naczynski DJ, Andelman T, Pal D, Chen S, Riman RE, Roth CM, Moghe PV. Albumin nanoshell encapsulation of near infrared excitable rare earth nanoparticles enhances biocompatibility and enables targeted cell imaging.  Small, 2010; 6;1631-40; DOI: 10.1002/smll.200902403.  Selected for issue cover.
  28. Waite CL, Roth CM. PAMAM-RGD conjugates enhance delivery of siRNA through a multicellular spheroid model of malignant glioma.  Chem., 2009; 20:1908-1916; PMCID:PMC3047462.
  29. Peddada LY, Harris NK, Devore DI, Roth CM. Novel graft copolymers enhance in vitro delivery of antisense oligonucleotides in the presence of serum.  Control. Rel., 2009; 140:134-140; PMCID: PMC2783907.
  30. Yang H, Roth CM, Ierapetritou MG. A rational design approach for amino acid supplementation in hepatocyte culture.  Bioeng., 2009; 103:1176-1191.
  31. Waite CL, Sparks SM, Uhrich KE, Roth CM. Acetylation of dendrimers for cellular delivery of siRNA.  BMC Biotechnol., 2009; 9:38; PMCID: PMC 2679008.
  32. Ierapetritou MI, Georgopoulos PG, Roth CM, Androulakis IP. Tissue-level modeling of xenobiotic metabolism in liver: An emerging tool for enabling clinical translational research.  Transl. Sci., 2009; 2:228-237; PMCID: PMC3068531.
  33. Roth CM. Quantitative measurements and rational materials design for intracellular delivery of oligonucleotides.  Prog., 2008; 24:23-28.
  34. Burley MR, Roth CM. Effects of retinoic acid on the proliferation and differentiation of HepG2 cells.  Open Biotechnol. J.; 2007; 1:47-51.
  35. Sundaram S, Lee LK, Roth CM. Interplay of polyethyleneimine molecular weight and oligonucleotide backbone chemistry in the dynamics of antisense activity.  Nucleic Acids Res., 2007; 35:4396-4408; PMCID: PMC1935005.
  36. Moghe PV and Roth CM. Multidisciplinary graduate curriculum on integrative biointerfacial engineering.  Eng. Educ., 2006; 40:251-258.
  37. Yang H, Yarmush ML, Roth CM, Ierapetritou MG. Minimal reaction sets and metabolic pathways for cultured hepatocytes.  Chem. Eng., 2006; 103:1176-1191.
  38. Lee LK, Dunham BM, Li Z, Roth CM. Cellular dynamics of antisense oligonucleotides and short interfering RNAs.  N.Y. Acad. Sci., 2006; 1082:47-51.
  39. Lee LK, Williams CL, Devore D, Roth CM. Poly(propylacrylic acid) enhances cationic lipid mediated delivery of antisense oligonucleotides.  Biomacromolecules, 2006; 7:1502-1508; PMCID: PMC2525803.
  40. Katz JM, Roth CM, Dunn MG. Factors that influence transgene expression and cell viability on DNA-PEI seeded collagen films. Tissue Eng., 2005; 11:1398-1406.
  41. Gevertz JL, Dunn SM, Roth CM. Mathematical model of real-time PCR kinetics.  Bioeng., 2005; 92:346-355.
  42. Sundaram S, Viriyayuthakorn S, Roth CM. Oligonucleotide structure influences the interaction between cationic polymers and oligonucleotides.  Biomacromolecules, 2005; 6:2961-2968; PMCID: PMC2519154.
  43. Roth CM. Molecular and cellular barriers limiting the effectiveness of antisense oligonucleotides.  J., 2005, 89:2286-2295; PMCID: PMC1366730.
  44. Jayaraman A, Yarmush ML, Roth CM. Evaluation of an in vitro model of hepatic inflammatory response by gene expression profiling.  Tissue Eng., 2005; 11:50-63.
  45. Roth CM, Sundaram S. Engineering synthetic vectors for improved DNA delivery: Insights from intracellular pathways.  Rev. Biomed. Engr., 2004; 6:397-426.
  46. Lee LK and Roth CM. Antisense technology in molecular and cellular bioengineering.  Opin. Biotechnol., 2003; 14:505-511.
  47. Roth CM. Quantifying gene expression.  Issues Mol. Biol., 2002; 4:93-100.
  48. Jayaraman A, Yarmush ML, Roth CM. Molecular bioengineering.  Eng. Chem. Res., 2002; 41:441-455.
  49. Walton SP, Stephanopoulos GN, Yarmush ML, Roth CM. Thermodynamic and kinetic characterization of antisense oligodeoxynucleotide binding to a structured mRNA.  J., 2002; 82:366-377; PMCID: PMC1302476.
  50. Jayaraman A, Walton SP, Yarmush ML, Roth CM. Rational selection and quantitative evaluation of antisense oligonucleotides.  Biophys. Acta, 2001; 1520:105-114.
  51. Roth CM, Kohen RL, Walton SP, Yarmush ML. Coupling of inflammatory cytokine signaling pathways probed by measurements of extracellular acidification rate. Chem., 2001; 89:1-12.
  52. Jayaraman A, Yarmush ML, Roth CM. Dynamics of gene expression in rat hepatocytes under stress.  Metabolic Eng., 2000; 2:239-251.
  53. Roy P, Roth CM, Margolies MN, Yarmush ML. Aromatic residues mediate the pressure-induced association of digoxigenin and antibody 26-10.  Chem., 1999; 83:171-177.
  54. Roy P, Roth CM, Margolies MN, Yarmush ML. Effect of pressure on antigen-antibody complexes: modulation by ionic strength and temperature.  Immunol., 1999; 36:1149-1158.
  55. Roth CM, Yarmush ML. Nucleic acid biotechnology.  Rev. Biomed. Engr., 1999, 1:265-297.
  56. Andreadis ST, Roth CM, Le Doux, JM, Morgan, JR, Yarmush, ML. Large-scale processing of recombinant retroviruses for gene therapy.  Prog., 1999, 15:1-11.
  57. Walton SP, Stephanopoulos GN, Yarmush ML, Roth CM. Prediction of antisense oligonucleotide binding affinity to a structured RNA target.  Bioeng., 1999; 65:1-9.
  58. Sundaram S, Roth CM, Yarmush ML. Pressure-induced dissociation of antigen-antibody complexes.  Prog., 1998; 14:773-781.
  59. Roth CM, Sader JE, Lenhoff AM. Electrostatic contribution to the energy and entropy of protein adsorption.  Colloid Interface Sci., 1998; 203:218-221.
  60. Rajur SB, Roth CM, Morgan JR, Yarmush ML. Covalent protein-oligonucleotide conjugates for efficient delivery of antisense molecules.  Bioconjugate Chem., 1997; 8:935-940.
  61. Roth CM, Reiken SR, Le Doux JM, Rajur SB, Lu X-M, Morgan JR, Yarmush ML. Targeted antisense modulation of inflammatory cytokine receptors.  Bioeng., 1997; 55:72-81.
  62. Roth CM, Lenhoff AM. Improved parametric representation of water dielectric data for Lifshitz theory calculations.  Colloid Interface Sci., 1996; 179:637-639.
  63. Roth CM, Unger KK, Lenhoff AM. A mechanistic model for retention in ion exchange chromatography.  Chromatogr., 1996; 726:45-56.
  64. Roth CM, Neal BL, Lenhoff AM. Van der Waals interactions involving proteins.  J., 1996; 70:977-987; PMCID PMC1224998.
  65. Roth CM, Lenhoff AM. Electrostatic and van der Waals contributions to protein adsorption:  comparison of theory with experiment.  Langmuir, 1995; 11:3500-3509.
  66. Roth CM, Lenhoff AM. Electrostatic and van der Waals contributions to protein adsorption:  computation of equilibrium constants.  Langmuir, 1993; 9:962-972.